EUVIMEDEUVIMED entdecken
Crossref

Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials

Helen Barnett, Melanie Guhl, Fulvio Di Stefano iD, Donia Skanji, Sandrine Guilleminot, Gaelle Saint-Hilary, Pavel Mozgunov, Marie-Karelle Riviere iD

Pharmaceutical Statistics · 2026-05 · 25 (3)

DOI: 10.1002/pst.70093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 19.04.2026. Verfasst von Helen Barnett und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematical Sciences, Lancaster University, Lancaster, UK. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leveraging preclinical prior information has the potential to enhance the efficiency of Phase I oncology trials if used appropriately. In this paper, a comparison of the meta‐analytic predictive (MAP) prior approach and the power prior approach is undertaken in application to a setting using the Bayesian Logistic Regression Model (BLRM). A novel methodology to determine the parameters of the two approaches based on external data is introduced. Moreover, the escalation with overdose control criterion, commonly used in conjunction with the BLRM, is extended via an additional criterion, which allows for less conservative escalation. It is found that the inclusion of animal data is recommended to be done using the flexible MAP prior, with a justified specification of prior exchangeability. However, the benefit over not including animal data must be weighed against the potential losses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicAntineoplastic AgentsNeoplasmsBayes TheoremAnimalsHumansDose-Response Relationship, DrugDrug Evaluation, PreclinicalLogistic ModelsMeta-Analysis as TopicResearch Design

Stichwörter der Autor:innen

Bayesiandose findingearly phasepreclinicalprior specification

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • School of Mathematical Sciences, Lancaster University, Lancaster, UK.
  • Department of Statistical Methodology, Saryga, France.
  • Dipartimento di Scienze Matematiche (DISMA) "Giuseppe Luigi Lagrange", Politecnico di Torino, Turin, Italy.
  • Department of Clinical Statistics, Institut de Recherches Internationales Servier, Gif-sur-Yvette, France.
  • Department of Translational Statistics, Institut de Recherches Internationales Servier, Gif-sur-Yvette, France.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

ORCID-Profile: Fulvio Di Stefano, Marie-Karelle Riviere

Zitieren

APA

Barnett, H., Guhl, M., Di Stefano, F., Skanji, D., Guilleminot, S., Saint-Hilary, G., Mozgunov, P., & Riviere, M. K. (2026). Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials. Pharmaceutical Statistics, 25(3). https://doi.org/10.1002/pst.70093

Vancouver

Barnett H, Guhl M, Di Stefano F, Skanji D, Guilleminot S, Saint-Hilary G, et al. Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials. Pharmaceutical Statistics. 2026;25(3). doi:10.1002/pst.70093

BibTeX
@article{Barnett2026,
  author = {Barnett, Helen and Guhl, Melanie and Di Stefano, Fulvio and Skanji, Donia and Guilleminot, Sandrine and Saint-Hilary, Gaelle and Mozgunov, Pavel and Riviere, Marie-Karelle},
  title = {Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {3},
  doi = {10.1002/pst.70093}
}
Kostenlos starten →